Drug intelligence / Profile preview

prodigiosene-4-hydroxytamoxifen conjugate 4c

Development stage
Preclinical
Lead developer
Dalhousie University
Modality
Small Molecules
Administration
Parenteral
01

Overview

prodigiosene-4-hydroxytamoxifen conjugate 4c is a synthetic small molecule conjugate consisting of a tripyrrolic prodigiosene pharmacophore linked to a 4-hydroxytamoxifen (afimoxifene) targeting moiety via an ester linker. Developed by researchers at Dalhousie University, this conjugate is designed to selectively target estrogen receptor (ER)-positive breast cancer cells, such as the MCF-7 cell line. The 4-hydroxytamoxifen component binds to the estrogen receptor, facilitating cellular uptake, while the prodigiosene component acts as a transmembrane anion transporter, disrupting intracellular pH, inducing apoptosis, and exhibiting nanomolar-range antiproliferative activity.

Other names
prodigiosene-4-hydroxytamoxifen conjugate 4cprodigiosene4-hydroxytamoxifen conjugate 4cprodigiosene 4-hydroxytamoxifen conjugate 4cprodigiosene-tamoxifen conjugate 4c
02

Targets

ESR1 (ERα)ESR2 (ERβ)

Beyond the preview

Go deeper on prodigiosene-4-hydroxytamoxifen conjugate 4c.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on prodigiosene-4-hydroxytamoxifen conjugate 4c.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call